Earnings Feed
Start Free
Stoke Therapeutics, Inc.·4

Jul 17, 4:37 PM ET

Harrison Seth Loring 4

4 · Stoke Therapeutics, Inc. · Filed Jul 17, 2026

Research Summary

AI-generated summary of this filing

Updated

Stoke Therapeutics (STOK) Director Seth Loring Gifts 151,595 Shares

What Happened

  • Seth Loring, a director of Stoke Therapeutics (STOK), reported a series of gift (code G) transactions on July 16, 2026 totaling 151,595 shares. Each transaction is reported at $0.00 (no consideration) and listed as derivative securities. The filing shows paired disposals and acquisitions, resulting in a net change of 0 shares in beneficial ownership.

Key Details

  • Transaction date: July 16, 2026; Form 4 filed July 17, 2026 (timely).
  • Total shares involved: 151,595 shares across multiple gift entries; all reported at $0.00.
  • Net effect: No net increase or decrease in reported beneficial ownership (disposals equal acquisitions).
  • Relevant footnotes: F1 — gifts reported for no consideration and exempt from short‑swing profit liability under Rule 16b‑5; F3 — some securities are held directly by the East Pillar 2026 Irrevocable Trust for which the reporting person is a board member and beneficiary (indicating transfers involving a trust).
  • Filing timeliness: Filed promptly (next business day), not marked late.

Context

  • Code G indicates gifts — these are transfers for no consideration and do not necessarily signal buy/sell sentiment by the insider. Because entries are labeled as derivative and tied to a trust (per footnote), this appears to reflect transfers of ownership/beneficial interest rather than open‑market trading.

Insider Transaction Report

Form 4
Period: 2026-07-16
Stoke Therapeutics, Inc.STOK
Harrison Seth Loring
Director
Transactions
  • Gift

    Stock Option (Right to Buy)

    [F1][F2]
    2026-07-16−29,555→ 0 total
    Exercise: $28.80Exp: 2029-09-09→ Common Stock (29,555 underlying)
  • Gift

    Stock Option (Right to Buy)

    [F1][F2][F3]
    2026-07-16+29,555→ 29,555 total(indirect: By Trust)
    Exercise: $28.80Exp: 2029-09-09→ Common Stock (29,555 underlying)
  • Gift

    Stock Option (Right to Buy)

    [F1][F4]
    2026-07-16−14,777→ 0 total
    Exercise: $26.53Exp: 2030-06-02→ Common Stock (14,777 underlying)
  • Gift

    Stock Option (Right to Buy)

    [F1][F4][F3]
    2026-07-16+14,777→ 14,777 total(indirect: By Trust)
    Exercise: $26.53Exp: 2030-06-02→ Common Stock (14,777 underlying)
  • Gift

    Stock Option (Right to Buy)

    [F1][F5]
    2026-07-16−11,650→ 0 total
    Exercise: $40.37Exp: 2031-06-07→ Common Stock (11,650 underlying)
  • Gift

    Stock Option (Right to Buy)

    [F1][F5][F3]
    2026-07-16+11,650→ 11,650 total(indirect: By Trust)
    Exercise: $40.37Exp: 2031-06-07→ Common Stock (11,650 underlying)
  • Gift

    Stock Option (Right to Buy)

    [F1][F6]
    2026-07-16−21,000→ 0 total
    Exercise: $12.96Exp: 2032-06-06→ Common Stock (21,000 underlying)
  • Gift

    Stock Option (Right to Buy)

    [F1][F6][F3]
    2026-07-16+21,000→ 21,000 total(indirect: By Trust)
    Exercise: $12.96Exp: 2032-06-06→ Common Stock (21,000 underlying)
  • Gift

    Stock Option (Right to Buy)

    [F1][F7]
    2026-07-16−19,441→ 0 total
    Exercise: $12.46Exp: 2033-06-12→ Common Stock (19,441 underlying)
  • Gift

    Stock Option (Right to Buy)

    [F1][F7][F3]
    2026-07-16+19,441→ 19,441 total(indirect: By Trust)
    Exercise: $12.46Exp: 2033-06-12→ Common Stock (19,441 underlying)
  • Gift

    Stock Option (Right to Buy)

    [F1][F8]
    2026-07-16−7,639→ 0 total
    Exercise: $16.41Exp: 2034-06-04→ Common Stock (7,639 underlying)
  • Gift

    Stock Option (Right to Buy)

    [F1][F8][F3]
    2026-07-16+7,639→ 7,639 total(indirect: By Trust)
    Exercise: $16.41Exp: 2034-06-04→ Common Stock (7,639 underlying)
  • Gift

    Stock Option (Right to Buy)

    [F1][F9]
    2026-07-16−29,747→ 0 total
    Exercise: $10.90Exp: 2035-06-02→ Common Stock (29,747 underlying)
  • Gift

    Stock Option (Right to Buy)

    [F1][F9][F3]
    2026-07-16+29,747→ 29,747 total(indirect: By Trust)
    Exercise: $10.90Exp: 2035-06-02→ Common Stock (29,747 underlying)
  • Gift

    Stock Option (Right to Buy)

    [F1][F10]
    2026-07-16−17,786→ 0 total
    Exercise: $29.46Exp: 2036-06-02→ Common Stock (17,786 underlying)
  • Gift

    Stock Option (Right to Buy)

    [F1][F10][F3]
    2026-07-16+17,786→ 17,786 total(indirect: By Trust)
    Exercise: $29.46Exp: 2036-06-02→ Common Stock (17,786 underlying)
Footnotes (10)
  • [F1]The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended.
  • [F10]The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the Issuer on the vesting date.
  • [F2]This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on March 21, 2022.
  • [F3]The securities are directly held by the East Pillar 2026 Irrevocable Trust (the "Trust"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity. The reporting person and certain of his immediate family members are beneficiaries of the Trust.
  • [F4]This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2021.
  • [F5]This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 8, 2022.
  • [F6]This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 7, 2023.
  • [F7]This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 13, 2024.
  • [F8]This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2025.
  • [F9]This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2026.
Signature
/s/ Jonathan Allan, Attorney-in-Fact|2026-07-17

Documents

1 file
  • 4
    form4-07172026_080716.xmlPrimary